Handelsavisen
prelaunch
Companies Healthcare 1784.TWO
17
1784.TWO TPEx Biotechnology & Medical Research

1784.Two

$72,70
Open in Charts → Attach watcher ⌖
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
P/E
EV / Rev
Div yield
1,16 %
Op margin
-1,2 %
ROE
4,0 %
Net margin
4,2 %
Debt / equity
0,09
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
Ex-dividend
TR 1Y
About

1784.TWO operates in the healthcare diagnostics industry, providing diagnostic solutions and related services to healthcare providers and patients.

Business. 1784.TWO operates in the healthcare diagnostics industry, providing diagnostic solutions and related services to healthcare providers and patients.

Classification92 %
SectorHealthcare
Business sectorPharmaceuticals & Medical Research
IndustryBiotechnology & Medical Research
ActivityHealthcare Diagnostics
Generated · model-assisted
Sell-side consensus
HOLD1 analysts
0 buy1 hold0 sell
Avg 12m price target

Analyst recommendations

1 analysts · consensus Hold
Buy0
Hold1
Sell0
12-month price target
Consensus of sell-side coverage.
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
Hold
1 analysts · indicative
Ownership
not yet wired
Profitability
4,0 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning 1784.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to 1784.TWO. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    1784.TWO operates in the healthcare diagnostics industry, providing diagnostic solutions and related services to healthcare providers and patients.

    Classification92 %
    SectorHealthcare
    Business sectorPharmaceuticals & Medical Research
    IndustryBiotechnology & Medical Research
    ActivityHealthcare Diagnostics
    AI synthesis
    GENERATED

    1784.TWO maintains a relatively strong liquidity position, with a current ratio of 4.62, indicating the company can cover its short-term liabilities more than four times over with its current assets. However, the company's free cash flow is negative at -139,066,000 TWD, and capital expenditures are also negative at -132,184,000 TWD, suggesting significant investment in long-term assets. The company's cash and equivalents amount to 73,932,000 TWD, but this is offset by long-term debt of 113,802,000 TWD, resulting in a net cash position that is negative after subtracting total debt.

    Profitability metrics for 1784.TWO show a return on equity of 4.04% and a return on assets of 1.67%. These figures are below the industry median for return on equity and return on assets, indicating that the company is underperforming its peers in terms of generating returns from equity and total assets. The company's operating income is negative at -14,384,000 TWD, while net income is positive at 51,426,000 TWD, suggesting that non-operating income or gains are contributing to profitability.

    The company's revenue is concentrated in a single segment, as no additional segments are disclosed in the financial data. Geographically, the company's exposure is primarily within its domestic market, with no specific international revenue breakdown provided. This concentration may pose a risk if the domestic market experiences economic downturns or regulatory changes.

    Looking at the company's growth trajectory, the current fiscal year is expected to see a slight decline in revenue, with analyst estimates projecting 1,220,000,000 TWD compared to the current revenue of 1,236,596,000 TWD. The next fiscal year is also expected to show a modest decline, with no significant growth anticipated. The company's operating cash flow is positive at 148,040,000 TWD, which supports its operations and helps fund capital expenditures.

    Risk factors for 1784.TWO include a medium liquidity risk, as indicated by the negative net cash position after subtracting total debt. The company's dilution risk is low, with no significant dilution potential reported. However, the negative free cash flow and capital expenditures suggest that the company may need to seek additional financing in the future, which could lead to increased debt or equity dilution.

    Recent events and filings do not indicate any major changes or risks for the company. The company's financial performance and strategic direction appear to be stable, with no significant events reported in the latest filings or transcripts.

    Key takeaways
    • 1784.TWO has a strong current ratio but faces challenges with negative free cash flow and capital expenditures.
    • The company's return on equity and return on assets are below industry medians, indicating underperformance in profitability.
    • Revenue is concentrated in a single segment, and geographic exposure is primarily domestic, which may increase risk.
    • Analyst estimates suggest a slight decline in revenue for the current and next fiscal years.
    • The company has a medium liquidity risk and a low dilution risk, but may need additional financing in the future.
    • "margin_outlook_rationale": "The company's operating income is negative, indicating potential margin pressures from rising costs or declining prices.",

    Bull / Bear case

    analysis pipeline
    — missing data

    In focus — financials by report

    Valuation

    Market price
    $72,70
    Market cap
    Enterprise value
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    P / Tangible book
    Tangible book
    $1.27B
    Net cash
    -$39.9M
    Current ratio
    4.6
    Debt / equity
    0.1
    ROA
    1.7%
    ROE
    4.0%
    Cash conversion
    288.0%
    CapEx / revenue
    -10.7%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Consensus distribution

    sell-side coverage
    Recommendation distribution1 analysts
    Strong buy0
    Buy0
    Hold1
    Sell0
    Strong sell0
    Operating income · consensus0 TWD

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin-1,2 %Above P75
    Net Margin4,2 %Above P75
    ROE4,0 %Above P75
    Capex / Rev-10,7 %Below median
    D/E0,09Below median
    Cash Conv2,88Best in class

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Capex To Revenue
      capital_expenditure / revenue
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    Source documents
    • 1784.TWO Market data — financials · 2026-05-26
    • Bionet Corp Market data — analyst estimates · 2026-05-26

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    1784.TWOCanonical
    TPEx · USD

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    — missing data
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage